<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000513012"><TermName>midostaurin</TermName><TermPronunciation>(MY-doh-STAW-rin)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called protein kinase inhibitors. Also called N-benzoyl-staurosporine and PKC412.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718422" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;midostaurin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718421" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;midostaurin&quot;" language="es" id="_4"/><SpanishTermName>midostaurin</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de la leucemia. Es un tipo de inhibidor de la proteína cinasa. También se llama N-benzoilo-estaurosporina y PKC412.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-10-14</DateFirstPublished><DateLastModified>2007-03-15</DateLastModified></GlossaryTerm>
